Figure 3. GCP II inhibition improved several pyridoxine-induced locomotor deficits.

(a) Walking performance was significantly reduced upon pyridoxine treatment with the control group being significantly different to both pyridoxine treated groups particularly on days 11 and 15. No significant difference was seen between the pyridoxine/vehicle versus pyridoxine/2-MPPA groups on these days. On day 18 and day 25 there was a significant difference between control and pyridoxine/vehicle. However, no difference was observed between the control and the pyridoxine/2-MPPA groups nor between the 2 pyridoxine-treated groups. (b) Pyridoxine intoxication significantly reduced rotarod performance without any benefits of GCP II inhibition. (c) Both pyridoxine groups had significantly increased percentage of foot faults compared to the control group and GCP II inhibition partially blocked this deficit (d). The pyridoxine intoxication significantly decreased distance travelled in an open field and GCP II inhibition partially prevented this decrease. N = 10/group. Data = mean ± SEM. * = p<0.05.